Promising Preclinical Data Support TPC-026 as a Novel Chronic Therapy for Metabolic Disorders Including Obesity

Contributed by: PR Newswire

Tags

TETRAPHARM-Data-Ann

More Like This

PR Newswire associated0

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics

PR Newswire associated0

ResoTher Pharma receives a €2.5 million grant from European Innovation Council (EIC) to support a Phase 2a clinical study of their Lead Candidate RTP-026 for Myocardial Infarction

PR Newswire associated0

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation

PR Newswire associated0

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress